170 related articles for article (PubMed ID: 2926196)
1. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
[TBL] [Abstract][Full Text] [Related]
2. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
Paulick R; Kaesemann H; Caffier H
Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
[TBL] [Abstract][Full Text] [Related]
3. [The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer].
Imamura Y; Yasutake K; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1501-7. PubMed ID: 2143888
[TBL] [Abstract][Full Text] [Related]
4. [Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer].
Möbus V; Paula J; Beck T; Crombach G; Kreienberg R
Geburtshilfe Frauenheilkd; 1993 Jan; 53(1):24-9. PubMed ID: 8440454
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of biochemical tumor markers in serum of patients with cancer of the ovary].
Kizawa I; Kikuchi Y; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Mar; 35(3):251-8. PubMed ID: 6833810
[TBL] [Abstract][Full Text] [Related]
7. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
11. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
Wang XY; Ye J; Feng SW; Lü WG; Wan XY; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):813-6. PubMed ID: 21211277
[TBL] [Abstract][Full Text] [Related]
12. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
Chen W; Luo RC; Fan WW; Ma SD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
[TBL] [Abstract][Full Text] [Related]
15. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.
Søgaard CH; Lindegaard JC; Havsteen H; Nielsen OS; Mogensen O
Gynecol Oncol; 2005 May; 97(2):410-2. PubMed ID: 15863138
[TBL] [Abstract][Full Text] [Related]
18. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
Lukácskó I; Hernádi Z; Sápy T; Borsos A
Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
[TBL] [Abstract][Full Text] [Related]
20. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
